Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Operating Income: 2015-2024

Historic Operating Income for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to -$121.3 million.

  • Seres Therapeutics' Operating Income rose 22.94% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.4 million, marking a year-over-year increase of 20.13%. This contributed to the annual value of -$121.3 million for FY2024, which is 37.82% up from last year.
  • As of FY2024, Seres Therapeutics' Operating Income stood at -$121.3 million, which was up 37.82% from -$195.1 million recorded in FY2023.
  • Seres Therapeutics' Operating Income's 5-year high stood at -$64.5 million during FY2021, with a 5-year trough of -$195.1 million in FY2023.
  • Its 3-year average for Operating Income is -$165.4 million, with a median of -$179.9 million in 2022.
  • As far as peak fluctuations go, Seres Therapeutics' Operating Income plummeted by 178.97% in 2022, and later skyrocketed by 37.82% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Operating Income stood at -$88.1 million in 2020, then rose by 26.82% to -$64.5 million in 2021, then slumped by 178.97% to -$179.9 million in 2022, then fell by 8.44% to -$195.1 million in 2023, then spiked by 37.82% to -$121.3 million in 2024.